Abstract
Breast cancer resistance protein (BCRP), also known as mitoxantrone resistance protein (MRX) or placenta ABC protein (ABC-P), is the second member of the ABCG subfamily of ABC transport proteins (gene symbol ABCG2). Transfection and enforced expression of BCRP in drug-sensitive cells confers resistance to mitoxantrone, doxorubicin, daunorubicin and topotecan. In this study the expression of BCRP gene was measured using TaqMan real-time PCR in 59 children with newly diagnosed AML. Nine patients were also analyzed in relapse. The median of BCRP gene expression was more than 10 times higher in patients who did not achieve remission after the first phase of chemotherapy (n = 24) as compared to patients who did achieve remission at this stage (n = 21; P = 0.012). In first relapse the expression of the BCRP gene was higher than at diagnosis (P = 0.038). Although high levels of BCRP gene expression were more frequent in subtypes of AML with a favorable prognosis, we found that within both risk groups (high and low risk), patients who expressed high levels of BCRP had a worse prognosis (P = 0.023). Our results strongly suggest that the expression of the BCRP gene reduces the response to chemotherapy in AML and that BCRP expression is higher at the time of relapse.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki DB, Niemeyer CM, Schwabe D, Selle B, Boos J, Kaehl J, Feldges A . Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group Leukemia 2001 15: 348–354
Stevens RF, Hann IM, Wheatley K, Gray RG . Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party Br J Haematol 1998 101: 130–140
Ross DD . Novel mechanisms of drug resistance in leukemia Leukemia 2000 14: 467–473
Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL . Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study Blood 1999 94: 1086–1099
Wood P, Burgess R, MacGregor A, Yin JA . P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival Br J Haematol 1994 87: 509–514
Lamy T, Goasguen JE, Mordelet E, Grulois I, Dauriac C, Drenou B, Chaperon J, Fauchet R, le Prise PY . P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML) Leukemia 1994 8: 1879–1883
Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O . Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry Blood 1995 85: 2147–2153
Sievers EL, Smith FO, Woods WG, Lee JW, Bleyer WA, Willman CL, Bernstein ID . Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK–16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group Leukemia 1995 9: 2042–2048
Zhou DC, Zittoun R, Marie JP . Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia Leukemia 1995 9: 1661–1666
Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH . Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia Blood 1995 85: 186–193
Filipits M, Suchomel RW, Zochbauer S, Brunner R, Lechner K, Pirker R . Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome Clin Cancer Res 1997 3: 1419–1425
Sauerbrey A, Zintl F, Hermann J, Volm M . Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL) Anticancer Res 1998 18: 1231–1236
Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA . Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines J Natl Cancer Inst 1999 91: 429–433
Rocchi E, Khodjakov A, Volk EL, Yang CH, Litman T, Bates SE, Schneider E . The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane Biochem Biophys Res Commun 2000 271: 42–46
Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M . A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance Cancer Res 1998 58: 5337–5339
Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD . A multidrug resistance transporter from human MCF-7 breast cancer cells Proc Natl Acad Sci USA 1998 95: 15665–15670
Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE . Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes Cancer Res 1999 59: 8–13
Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH . Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues Cancer Res 2001 61: 3458–3464
Ross DD, Karp JE, Chen TT, Doyle LA . Expression of breast cancer resistance protein in blast cells from patients with acute leukemia Blood 2000 96: 365–368
Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG . Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia Br J Haematol 2001 115: 257–6262
Steinbach D, Dorffel W, Eggers G, Holfeld E, Kluba U, Krause I, Lauterbach I, Reiss T, Rieske K, Scharfe V, Schumacher R, Weigel H, Weinmann G, Zintl F, Hermann J . Improved results in the treatment of acute myeloid leukemia – results of study AML-BFM-93 in East Germany with comparisons to the preceding studies AML-I-82 and AML-II-87 Klin Padiatr 2001 213: 162–168
Steinbach D, Hermann J, Littlewood T, Zintl F . Risk group definition in children with acute myeloid leukemia by calculating individual risk factors on the basis of a multivariate stepwise Cox regression analysis Leuk Lymphoma 2001 42: 1289–1295
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steinbach, D., Sell, W., Voigt, A. et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16, 1443–1447 (2002). https://doi.org/10.1038/sj.leu.2402541
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402541
Keywords
This article is cited by
-
The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches
Cellular Oncology (2020)
-
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics
Scientific Reports (2017)
-
Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein
Cancer Chemotherapy and Pharmacology (2016)
-
SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis
Leukemia (2014)
-
Impact of ABC transporters, glutathione conjugates in MDR and their modulation by flavonoids: an overview
Medicinal Chemistry Research (2014)